PR
SUPN icon

PSP Research’s Supernus Pharmaceuticals SUPN Stock Holding History

PSP Research’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$279K Hold
6,000
– – 0.15% 52
2026
Q1 		$310K Sell
6,000
-4,758
-44% -$242K 0.22% 58
2025
Q4 		$535K Buy
+10,758
New +$523K 0.47% 30

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

PSP Research's SUPN Position: Q2 2026 in Review

PSP Research held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 6,000 shares worth $279K. The position accounts for 0.15% of the portfolio, ranked #52.

PSP Research first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $535K in Q4 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • PSP Research held 6,000 shares of Supernus Pharmaceuticals worth $279K as of Q2 2026.
  • PSP Research left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up 0.15% of PSP Research's portfolio in Q2 2026, its #52 holding.
  • PSP Research first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Supernus Pharmaceuticals position peaked at $535K in Q4 2025.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.